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Immunoglobulin (Ultravenous, IGIV) is now used in a
variety of immune-mediated diseases. Its presumed
mechanism of action involves both anti-in£ammatory
and immunomodulatory activities. A number of der-
matologic conditions are believed to be immune medi-
ated and in these disorders, IGIV has shown bene¢t in
reducing symptoms and the need for cortecosteroids or
cytotaxic drugs. In many of these diseases, the initial
bene¢ts seen in open-labeled trials must be con¢rmed
in controlled clinical trials. Key words: IGIV, determatology,
anti-in£ammatory immunomodulatory. J Investig Dermatol
Symp Proc 9:92 ^96, 2004
INTRODUCTION
A
dministration of immunoglobulin (Ig) was initiated
for the treatment of antibody de¢ciency disorders
¢ve decades ago. With the advent of signi¢cant
changes in manufacturing, Ig products became
available for intravenous use in the 1980s. This al-
lowed for much broader therapeutic application because of the
ability to deliver higher doses. Whereas Ig replacement in anti-
body de¢ciency disorders was begun at 100 mg/kg body weight,
IGIV (immunoglobulin intravenous, human), treatment of the
wider range of disorders appeared to require doses exceeding
1 g/kg body weight. The ¢rst indication of the therapeutic poten-
tial of IGIV beyond simple Ig replacement was the successful
treatment of patients who had concomitant primary immune de-
¢ciency and thrombocytopenia purpura. Here, IGIV was admi-
nistered at a dose of 400 mg/kg body weight for 5 consecutive
days (Imbach et al, 1981).
In fact, indications of and support for the broader potential of
Ig products was seen by a number of clinicians managing patients
with primary immunode¢ciency. Even doses of intramuscular Ig
of 100 mg/kg body weight had surprising consequences of repla-
cement therapy that went well beyond simple prevention of in-
fection through provision of antibodies. Some of these responses
are summarized in Table 1. They include reversal of signi¢cant
immune-mediated cytopenias, including neutropenia and throm-
bocytopenia (Gelfand, 1988), lymphoid hyperplasia, reactive air-
way disease, growth attenuation, diarrhea, arthritis (Stuckey
et al, 1978), concentration de¢cits, andpertinent to this discus-
siona number of dermatologic abnormalities that accompany
some immunode¢ciency disorders. In this regard, Ig replacement
therapy has been shown to impact the cutaneous lesions of eczema,
alopecia totalis, or nondescript rashes (Ipp and Gelfand, 1976). For
each of these conditions, when seen in patients with primary
antibody de¢ciency, monthly injections of IgG resulted in a nor-
malization of the skin condition and even reappearance of ¢ne
hair in patients with alopecia. In many of these patients, the con-
dition recurred when Ig therapy was stopped or delayed, only to
respond again on reinstitution of therapy.
It was these clinical observations that spurred the consideration
and expansion of IGIV use in a wide variety of disorders. A par-
tial list of potentially responsive conditions is included inTable 2.
It should be recognized that in some but not all of these condi-
tions placebo-controlled trials have been carried out to provide
validation. In many, a series of isolated reports, often anecdotal,
are the basis for inclusion in the list.
MECHANISM OFACTION OF IGIV
A major de¢cit in rationally and appropriately administering
IGIV to this wide range of disorders with seemingly di¡erent
pathophysiologies is the lack of knowledge on how and why
IGIVmay work. Depending on the disease target, IGIV has been
shown to exhibit anti-in£ammatory and/or immunomodulatory
activities.The anti-in£ammatory potential of IGIV is perhaps best
seen in the treatment of Kawasaki syndrome (KS), an acute sys-
temic vasculitis, primarily in infants, that mainly involves the
medium and large arteries. Although clinical and epidemiological
¢ndings suggest an infectious etiology, this remains to be proved.
IGIV therapy has profound e¡ects in KS, rapidly reducing fever,
irritability, cutaneous manifestations, and, importantly, reducing
the prevalence of coronary artery abnormalities. As summarized
in Table 3, all of the clinical and laboratory ¢ndings support a
potent anti-in£ammatory e¡ect of IGIV in KS, but the exact me-
chanism of action is not de¢ned.
Equal to the number of diseases potentially responding to
IGIV are the suggested mechanisms of action (Table 4). Some of
these are speculative, whereas others have received some experi-
mental support. A few of the mechanisms pertinent to the der-
matologic diseases are discussed below.
FC receptor interactions Following the successful treatment
of immune-mediated thrombocytopenia, IGIV was postulated
to act by blocking Fc receptors on phagocytic cellsfor
example, on splenic macrophagespreventing antibody (IgG)-
coated platelets from interacting with these cells and enhancing
platelet survival. In fact, in direct testing, survival of IgG-coated
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red cells was signi¢cantly enhanced in individuals receiving IGIV
(Fehr et al, 1982).
Recently, a murine model of ITP was used to delineate the
molecular basis for IGIV (Samuelsson, 2001). In these studies,
administration of clinically protective doses of intact antibody
or monomeric Fc fragments to wild-type or Fcg receptor^
humanized mice prevented platelet consumption initiated by
injection of a platelet-directed antibody. Of importance, the
inhibitory (signaling) Fc receptor, FcgRIIB, was required for
this protection. Any interference with this inhibitory receptor
reversed the therapeutic bene¢t of IGIV. The protective e¡ects
were associated with the ability of IGIV to upregulate the
expression of FcgRIIB on splenic macrophages. This demo-
nstration of the modulation of an inhibitory signaling pathway
may provide an important foundation for the therapeutic
applications of IGIV in attenuating or reversing (auto)antibody-
mediated diseases.
Reduction in pathogenic autoantibody titers A number of
disorders in which IGIV exhibits immunomodulatory/anti-
in£ammatory e¡ects are associated with autoantibodies that may
be pathogenic. Thus, reducing the levels of these autoantibodies,
either by limiting production or enhancing catabolism, could
prove bene¢cial. Several studies have shown that IGIV, at least in
vitro, can interfere with Ig synthesis. This could be the result of
the activation of FcgRIIB, the inhibitory signaling pathway on
B lymphocytes.
A number of possible mechanisms could trigger enhanced
catabolism or degradation of serum autoantibody levels. There is
evidence that IGIV contains an array of anti-idiotypes and that it
may act through idiotypic suppression of autoantibody
formation. Idiotypic suppression could directly modify B cell
function, limiting antibody synthesis, or it could do so by
neutralizing the autoantibody following interaction with the
idiotype. In addition, anti-idiotypic antibodies may combine
with idiotypes on the autoantibodies, thus forming complexes
and so further enhancing catabolism (Rossi et al, 1989;
Kazatchkine and Kaveri, 2001).
An interesting mechanism that may be responsible for
enhanced catabolism involves the interactions between IGIV and
FcRn receptors (Yu, 1999). Normally, IgG binds to FcRn that are
found in many tissues, including skin and muscle, and that are
highly expressed on vascular endothelial cells. FcRn is a
protective receptor that prevents the catabolism of IgG. IgG
binds to FcRn in endocytic vesicles, preventing its degradation
by lysosomes; as a result, it returns intact to the circulation.
Increasing the amounts of IgGfor example, by administration
of IGIV, may saturate FcRn, thereby accelerating the rate of
catabolism of pathogenic IgG autoantibodies.
Induction/suppression of cytokines There are numerous
reports that IGIV modulates the synthesis and release of certain
cytokines and cytokine antagonists. Thus, administration of
IGIV or inclusion of IGIV in in vitro culture systems has been
shown to downregulate the production of the pro-in£amma-
tory cytokines IL-1 and tumor necrosis factor a (TNF-a), at the
same time up-regulating monocyte production of the anti-
in£ammatory proteins IL-1 receptor antagonist (IL-1Ra) and IL-
10. Following IGIV infusion, soluble TNF-a receptor, IL-6, IL-4
receptor, and IL-10 levels may increase, as do levels of TGF-b
(Anderson, 1984; Shimozato et al, 1991; Arend and Leung, 1994;
Campbell et al, 1999; Ruetter and Luger, 2001).
Table1. Additional Bene¢ts of Ig Replacement in Antibody-
De¢cient Patients
^ Reversal of autoimmune cytopenias
^ Neutropenia
^ Thrombocytopenia
^ Improvement in skin disorders
^ Eczema
^ Alopecia totalis
^ Unde¢ned rashes
^ Diminution of lymphoid hyperplasia
^ Resolution of arthritis
^ Decrease in diarrhea
^ Improvement of reactive airway disease
^ Acceleration of linear growth
^ Increase in growth hormone production
^ Increase in mental concentration
Table 2. Diseases that Respond to IGIV Therapy
Diseases Responding to IGIV Therapy in Controlled Trials
Antibody de¢ciency diseases
Idiopathic thrombocytopenia purpura
Pediatric HIVdisease
Kawasaki syndrome
Dermatomyositis
Guillain-Barre syndrome
Chronic in£ammatory demyelinating polyneuropathy
Multifocal motor neuropathy
Sti¡ man syndrome
FDA approved indication.
DiseasesWhich Appear to Respond in Clinical Trials But Need Further Veri¢-
cation Steroid-dependent asthma ANCA-positive vasculitis Multiple sclerosis
Myasthenia gravis Lambert-Eaton syndrome Toxic shock syndrome
Table 3. Anti-In£ammatory E¡ects of IGIV in Kawasaki
Syndrome
Decreased temperature
Decreased white blood cell count
Decreased serum levels of acute phase reactants
alpha1-antitrypsin
¢brinogen
c-reactive protein
Decreased serum soluble IL-2 receptors
Table 4. ImmunoregulatoryActions of IGIV
In£ammation
^ Attenuation of complement-mediated damage
^ Decrease in immune-complex-mediated in£ammation
^ Induction of anti-in£ammatory cytokines
^ Inhibition of activation of endothelial cells
^ Neutralization of microbial toxins
^ Reduction in corticosteroid requirements
Cell growth
^ Regulation of apoptosis pathways
^ Inhibition of lymphocyte proliferation
Tcells
^ Regulation of the production of T-cell cytokines
^ Neutralization of T-cell superantigens
B cells and antibodies
^ Control of emergent bone marrow B-cell repertoires
^ Negative signaling through inhibitory Fcg receptors
^ Selective down-regulation or up-regulation of antibody production
^ Neutralization of circulating autoantibodies by anti-idiotypes
Fc receptors
^ Blockade of Fc receptors on macrophages and e¡ector cells
^ Induction of antibody-dependent cellular cytotoxicity
^ Induction of inhibitory Fcg receptors IIB
^ Saturation of FcRn
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IGIV may itself contain a number of cytokines, cell surface
molecules, and antibodies that can regulate immune/
in£ammatory activities. They include CD4, CD5, T cell receptor
Vb regions, MHC class I and II, CD40, IL-1a, IFN-a, and GM-
CSF (Kazatchkine et al, 1994; Aukrust et al, 1994; Hurez et al, 1994;
Kaveri et al, 1996; Prasad et al, 1998;Viard et al, 1998).
E¡ects of IGIV on apoptosis Alterations in the control of
apoptosis can result in the development of a number of diseases.
Defective regulation of apoptosis has been associated with many
autoimmune diseases. Apoptosis is tightly regulated, principally
by one of two pathways: interaction between the death receptor
TNFR1 and Fas with its ligand, and the participation of
mitochondria. These pathways are tightly regulated by members
of the BCL-2 family.
IGIV contains both agonistic and blocking antibodies to Fas
(CD95), the receptor for Fas-Ligand (FasL), which transduces
apoptotic signals into cells. Such antibodies can induce apoptosis
of FasL-expressing lymphocytic cells and monocytic cells
(Prasad, 1998; Viard, 1998). Death of cells involves caspases 1 and
3. However, not all cell death mediated in this way may be Fas
mediated.
In KS, IGIV-induced apoptosis of KC neutrophils in vitro and
in vivo decreases the numbers of circulating neutophils by
accelerating apoptosis. This appeared to be Fas independent
(Tsujimoto et al, 2002).
Neutralization of bacterial toxins A number of bacterial
exotoxins can act as ‘‘superantigens,’’ activating a large fraction of
T lymphocytes and thus causing the release of numerous
cytokines. The di¡erent exotoxins show di¡erent speci¢cities for
the b chain of the T cell receptor. IGIV contains antibodies to a
number of bacterial exotoxins, preventing their interaction with
T lymphocytes. As a result, IGIV can prevent T cell stimulation
and proliferation induced by these toxins. Moreover, the
antibodies in IGIV can prevent binding or presentation of toxins
by antigen-presenting cells (Takei et al, 1993).
Alteration in steroid sensitivity For many of these immune-
mediated in£ammatory disorders, corticosteroids are a mainstay
of therapy. It is now increasingly appreciated that in£ammation
may be associated with corticosteroid insensitivity or resistance.
In part, this may be mediated by T lymphocytes as the
cytokines, IL-2 and IL-4 play a major role in reducing human T
cell sensitivity to corticosteroids. These cytokines induce changes
in corticosteroid receptor (GCR)^binding a⁄nities; the number
of receptors remains the same. To some extent, the resistance to
steroids may also re£ect an increase in the expression of the
inactive isoform of the receptor GCR-b (Leung et al, 2002).
Both in vitro and in vivo, IGIV has been shown to normalize or
reverse corticosteroid insensitivity (Spahn et al, 1999), a response
that may in fact be attributable, at least in part, to its e¡ects on
cytokine production. In fact, IGIV is a potent suppressor of T
cell production of IL-2 and IL-4 in vitro (Modiano et al, 1997).
This improvement in steroid sensitivity with IGIV may underlie
some of the responses seen in the wide variety of immune-
mediated diseases where IGIV has shown bene¢t.
Use of IGIV in dermatological conditions A number of
presumed immune-mediated skin diseases has been the target of
IGIV therapy (Table 5). Although IGIV is emerging as a major
treatment for this group of disorders, few reports of controlled
trials are available. In the majority, dosages of IGIV of 1^2 g/kg
body weight were used on a monthly basis for induction of
remission and at greater intervals once remission was achieved.
Autoimmune blistering diseases The major group of
autoimmune blistering disorders, pemphigus, is associated with
circulating IgG autoantibodies against cell surface molecules on
keratinocytes. Diseases within the pemphigus group are usually
treated with systemic corticosteroids plus/minus immuno-
suppressive drugs. In pemphigus vulgaris, desmoglein 3 serves as
a target antigen expressed on basal keratinocytes (Thivolet, 1994;
Stanley, 1997). A number of clinical reports have demonstrated
the successful use of IGIV therapy in pemphigus patients
(Harman and Black, 1999; Messer et al, 1995; Bewly and Keefe,
1996;Weaver et al, 1996; Colonna et al, 1998; Engineer et al, 2000;
Ahmed 2001a). Although not universal, the responses appeared
rapidly with stabilization of the disease. Improvement lasted
from 6 weeks to 14 months and in most cases enabled reduction
of corticosteroids or immunosuppressive/cytotoxic drugs.
Improvement in the skin condition was associated with decreases
in pemphigus antibody titers (Bystryn et al, 2002), including
speci¢c antibodies to desmoglein 3 and 1.1 The decline in
antibodies did not appear to be due to interference with
synthesis but resulted from increased IgG catabolism (Bystryn,
2002).
In pemphigus foliaceus, the target antigen appears to be
desmoglein 1, an epidermal cadherin molecule predominantly
expressed in the upper layers of the epidermis (Thivolet, 1994;
Stanley, 1997). A report of IGIV as monotherapy in 11 patients
with foliaceus suggested a favorable response in all and a
sustained clinical remission of 18 months after discontinuation.
(Ahmed and Sami 2002). After 4 months of IGIV therapy,
reductions in titers of antibodies to desmoglein 1 were detected;
the titers disappeared by 13 months.2 Other studies have shown
similar bene¢t (Enk and Knop, 1998).3
Bullous pemphigoid is characterized by deposition of IgG and
C3 at the basement membrane.The target antigens are BPAg1 and
BPAg2 within hemidesmosomes (Amagal, 1995). In di¡erent
reports of more than 40 patients, and despite the use of di¡erent
protocols, IGIV appeared to be a promising alternative, especially
Table 5. IGIV Treatment of Immune-Mediated Skin Diseases
Autoimmune Blistering Diseases E⁄cacy of IGIV
Pemphigus
Bullous pemphigoid þ
Pemphigus vulgaris þ
Pemphigus foliaceus þ
Oral pemphigoid (þ )
Ocular cicatricial pemphigoid (þ )
Epidermolysis bullosa acquisita (þ )
Pemphigoid gestationes (þ )
Linear IgA bullous dermatosis (þ )
Dermatomyositis þ
SLE cutaneous (þ )
Scleroderma (þ )
Toxic epidermal necrolysis þ
Stevens-Johnson syndrome (þ )
Atopic dermatitis þ
Hyperimmunoglobulinemia E syndrome (þ )
Chronic autoimmune urticaria þ
Pyoderma gangrenosum (þ )
Erythema exsudativum multiforme (þ )
Graft versus host disease (?)
þ : Series of studies, reports
(þ ): Limited studies, reports, patient numbers
(?): No obvious bene¢t
1Sami N, Ali S, Bhol KC, Ahmed AR: In£uence of intravenous immu-
noglobulin therapy on autoantibody titers to BP Ag1 and BP Ag2 in
patients with bullous pemphigoid. Submitted, 2002
2Sami N, Bhol KC, Ahmed AR: In£uence of intravenous immunoglo-
bulin therapy on antibody titers to desmoglein 3 and desmoglein 1 in
patients with pemphigus vulgaris. Submitted, 2002
3Sami N, Bhol KC, Ahmed AR: In£uence of IVIG therapy on autoanti-
body titers to desmoglein 1 in patients with pemphigus foliaceus. Sub-
mitted, 2002
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in patients for whom conventional therapy had failed (Ruetter
et al, 1994; Ahmed, 2001b). Antibody levels to BPAg1 and BPAg2
were shown to progressively decrease and ultimately reach levels
that indicated a serological remission (Sami et al, 2002d).
Epidermolysis bullosa acquisita (EBA), a chronic severe
disease, involves subepithelial blister formation of the skin and
mucous membranes. A target antigen has been identi¢ed: the c-
terminus of type VII procollagen within the anchoring ¢brils at
the dermal^epidermal junction (Shimizu et al, 1990). Although
only a handful of treated patients have been reported, IGIV
appears to arrest the disease and allow ancillary medications to
be reduced (Mohr et al, 1995; Koller et al, 1997). Autoantibody
titers may not have decreased despite the clinical response.
Pemphigoid gestationes is a blistering disorder restricted to the
second or third trimester of pregnancy. Autoantibodies to a
hemidesinosomal antigen have been described. Reports of
treatment with IGIV are very limited (Hen et al, 1998; Engineer
and Ahmed, 2001).
Linear IgA bullous dermatosis is a blistering autoimmune
disease characterized by IgA deposition along the basement
membrane. Two reports of successful use of IGIV are noted
(Khan et al, 1999; Kroiss et al, 2000).
Oral pemphigoid is a chronic autoimmune disease involving
the oral cavity, characterized by a homogenous linear deposition
of Ig and complement along the basement membrane and
subepithelial blister formation. The a6/b4 integrin heterodimer
may be a target, as autoantibodies to a6 can be detected. In a
study of seven patients with severe disease, treatment with IGIV
induced a clinical response after four months. This resulted in a
prolonged and sustained remission associated with a reduction in
anti-a6 antibody titers (Sami et al, 2002e).
Ocular cicatricial pemphigoid (OCP) is another blistering
autoimmune disease with autoantibodies to b4 integrin,
a¡ecting the eye, skin, and mucous membranes. Serum IL-1
levels are markedly elevated in these patients. In eight patients,
IGIV therapy resulted in a marked decrease in conjunctival
in£ammation, decreases in titers of anti-b4 antibodies, lower IL-
1 levels, and increased IL-1 receptor antagonist levels (Letko et al,
2000; Kumari et al, 2001).
Toxic epidermal necrolysis This rare but severe exfoliative,
often drug-induced, disorder is associated with high mortality.
Alterations in control of keratinocyte apoptosis may play a role.
Upregulation of keratinocyte FasL expression may be the critical
trigger of cell destruction (Viard, 1998). Several reports in open
trials have documented impressive and life-saving improvement
with IGIV in the majority of patients treated (Viard, 1998).
Dermatomyositis This systemic autoimmune disease is charact-
erized by a chronic skeletal-muscular in£ammatory response and
signi¢cant muscle weakness. There is no known cause. Of note, a
major pathological feature besides the in£ammatory cell in¢ltration
along the basement membrane of the muscle ¢bers is the deposition
of complement, the membrane attack complex C5b-C9, in
intramuscular capillaries. In a number of clinical trials, IGIV has
shown e⁄cacy in returning muscle strength, reducing creatin
kinase levels, and reducing the need for corticosteroids (Roifman
et al, 1987; Dalakas et al, 1993; Collet et al, 1994; Sabroe et al, 1995;
Furuya et al, 1998). Both muscle and cutaneous (ulcer)
manifestations respond. In keeping with the reported activity of
IGIV in preventing membrane attack complex formation,
deposition of C5b-C9 was markedly reduced, as was muscle
ICAM-1,TGF-b, and MHC class I expression (Dalakas, 1993).
Atopic dermatitis Atopic dermatitis is an eczematous in£a-
mmatory skin disease occurring in genetically predisposed
individuals, prone to develop atopic disease. It can be triggered by
a number of environmental factors, foods, and allergens, and is
characterized by a T helper 2 (TH2)^biased response with elevated
serum IgE levels, eosinophilia, and elevated TH2 cytokine levels,
including IL-4. Often, there is marked superinfection with Sta-
phylococcus infection. In part, the disease may be aggravated by
bacterial exotoxins triggering cytokine release.
In a number of open trials, IGIV has proved bene¢cial in
patients requiring oral corticosteroids. It can result in a rapid
resolution of pruritus and restore TH cell subset balance, and it
can reduce the frequency of IL-4^producing cells while
increasing IFN-g secreting cells as well as modi¢ng skin test
reactivity, thus improving symptom scores and reducing the
need for corticosteroids (Gelfand et al, 1996; Jolles et al, 1999). A
signi¢cant bene¢t of IGIV in AD may be attributable to the
neutralization of bacterial exotoxins (‘‘superantigens’’), as
discussed above.
As indicated inTable 5, there are a number of other cutaneous
disorders where IGIV has shown bene¢t, albeit in open trials. In
these diseases, IGIV may o¡er some promise as an alternative
therapy where conventional approaches are either not e¡ective
or associated with signi¢cant toxicity.
SELECTION OFAN IGIV PREPARATION
As discussed above, in most instances, IGIV was used at a total
dose of B2 g/kg body weight on a monthly basis. This is the
typical way IGIV is used in the treatment of most immune-
mediated diseases. The fact that few if any direct comparisons of
di¡erent products have been carried out does not infer that all
IGIVs are the same. The di¡erent manufacturing processes, the
formulation, and the composition of the ¢nal product all may
contribute to convenience, tolerability, safety, and e⁄cacy. In
general, liquid preparations of IGIV are favored over lyophilized
products. The higher the concentration of the solution, the more
convenient in terms of time for infusion and safety: A 10% solu-
tion requires half the volume and likely half the time to infuse.
Products that are hyperosmolar, contain sugars to prevent aggre-
gate formation, or contain signi¢cant salt concentrations have
been associated with an increase in adverse events, especially
at the high doses used in the treatment of these autoimmune
disorders.
SUMMARY
As with other immune-mediated diseases, IGIV is emerging as an
important alternative in the treatment of a number of immune-
mediated skin diseases. Where conventional therapies of these
disorderscorticosteroids and immunosuppressive drugshave
failed or proved too toxic to continue treatment, IGIV has pro-
vided sustained clinical remission, especially in the group of
autoimmune blistering diseases. The underlying mechanisms of
action are not clear but may re£ect a combination of immuno-
modulatory and anti-in£ammatory activities, enhancement of
steroid sensitivity, and catabolism of pathogenic autoantibodies.
Optimization of IGIV therapy in these diseases must await
further delineation of the mechanism of action. This is essential,
as therapy is expensive and utilizes blood products that are not in
unlimited supply. For these reasons, carefully controlled clinical
trials are necessary not only to establish e⁄cacy but also to pro-
vide needed guidelines for dosing, frequency, and even selection
of the best product for speci¢c patients.
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